Oxaminozoline; Hyperium; N-(Dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; Rilmenidine [INN]; Rilmenidia [Spanish]; Rilmenidinum [Latin]; N-(Dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-; UNII-P67IM25ID8; Oxazolidine, 2-((dicyclopropylmethyl)imino)-; P67IM25ID8; Rilmenidine (INN); NSC664312; NCGC00015884-09; DSSTox_CID_25194; DSSTox_RID_80741; DSSTox_GSID_45194; NSC 664312; Oxaminozoline; Rilmenidene;S 3341; SR-01000002992; EINECS 259-021-0; S 3341; BRN 1211287; Hyperium (TN); Methylamine, 1,1-dicyclopropyl-N-(2-oxazolinyl)-; 2-Oxazolamine, 4,5-dihydro-N-(dicyclopropylmethyl)-; Tocris-0790; ARSENICTRIFLUORIDE; Lopac-R-134; Prestwick0_000982; Prestwick1_000982; Prestwick2_000982; Prestwick3_000982; Lopac0_001104; BSPBio_001043; SCHEMBL114420; SPBio_002944; BPBio1_001149; CHEMBL289480; ZINC9708; DTXSID3045194; HMS2089G15; HMS3263M10; Tox21_110254; Tox21_501104; BDBM50070328; MFCD00865924; 2-(dicyclopropylmethylamino) oxazoline; AKOS006273431; Tox21_110254_1; AB07513; CCG-205180; DB11738; LP01104; NSC-664312; SDCCGSBI-0051073.P002; NCGC00015884-01; NCGC00015884-02; NCGC00015884-03; NCGC00015884-04; NCGC00015884-05; NCGC00015884-06; NCGC00015884-07; NCGC00015884-08; NCGC00015884-10; NCGC00015884-11; NCGC00015884-13; NCGC00015884-19; NCGC00021689-02; NCGC00021689-04; NCGC00021689-05; NCGC00021689-06; NCGC00261789-01; (N-dicyclopropylmethyl)-amino-2-oxazoline; NCI60_022181; SY267932; DB-052512; HY-100490; AB00514648; CS-0019423; EU-0101104; FT-0630668; R-134; C11120; D08482; AB00513728-09; 187R041; L001230; Q967973; N-(Dicyclopropylmethyl)-4,5-dihydro-2-oxazolamine;; SR-01000002992-3; SR-01000002992-4; W-105661; N-(Dicyclopropylmethyl)-N-(4,5-dihydro-1,3-oxazol-2-yl)amine